The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
about
Combined surgical and molecular therapy: the gastrointestinal stromal tumor modelGlucose metabolism in gastric cancer: The cutting-edgePerformance evaluation of endoscopic Cerenkov luminescence imaging system: in vitro and pseudotumor studiesParametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumours.Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET.Imaging gastrointestinal stromal tumors.Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate.Diagnosis and evaluation of gastric cancer by positron emission tomographyMetabolic regulation of cancer cell side population by glucose through activation of the Akt pathway.CT features, mimics and atypical presentations of gastrointestinal stromal tumor (GIST).Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT.Assessment of tumor response to tyrosine kinase inhibitorsSystematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose.Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group.Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.Technology insight: PET and PET/CT in head and neck tumor staging and radiation therapy planning.(18)F-FDG PET in sarcoma treatment response imaging.The radiology of gastrointestinal stromal tumours (GIST)Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment.Positron emission tomography: clinical applications in oncology. Part 2.Role of PET/PET-CT in the management of sarcomas.Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice.The evolving role of nuclear molecular imaging in cancer.Noninvasive prediction of tumor responses to gemcitabine using positron emission tomographyPredictive and prognostic value of FDG-PET.Multidisciplinary treatment of gastrointestinal stromal tumors.Visualizing cancer and immune cell function with metabolic positron emission tomography.Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors modelHepatic metastases of gastric adenocarcinoma showing metabolic remission on FDG-PET despite an increase in size on CT.PET imaging for Treatment Response in CancerThe clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection.Role and cost effectiveness of PET/CT in management of patients with cancer.Response assessment in gastrointestinal stromal tumor.Convergence technology in cancer medicine.F-FDG PET Imaging in the Evaluation of Treatment Response to New Chemotherapies beyond Imatinib for Patients with Gastrointestinal Stromal Tumors.FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.The value of (18) F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis.Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.Benign mesocolon schwannoma in PET/CT and immunohistochemistry assessment: a case report.Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
P2860
Q24675987-B5E748DA-E144-4193-82A9-BC441A19A295Q26766098-6D650668-1133-4721-BEBB-E1BDB724D537Q28654477-EBA4A1DA-4591-462E-BE02-4DCF75866E3AQ33844776-ECD3F2AA-D9D4-4712-A7AE-67BA8FCBBF39Q34164758-FF5A8E10-C078-4F4B-84DF-6D95640040BEQ34414114-196F624E-E53F-40A3-8D09-7C07E9F6C921Q34596126-78DD50BC-A096-40F5-B250-ED60E8925A09Q34661633-8E297375-B08D-4F15-A553-7EB5CE0FAE35Q35008587-04ECBD93-1EE7-42B4-98BE-FAB42CC90C3AQ35307257-E1D2D23E-852D-45B4-A44C-0C3992C9BC1EQ35535875-84A59381-16B8-42D1-A363-247A1706973CQ35558589-B91C9F95-2937-4E3D-9D30-06AC355D2E09Q35947339-D3A23AC8-614E-49F6-9C1E-D3C157F24C76Q35996655-5C468C94-EA7B-4D75-B038-8F6BDB3C89E9Q36180074-5EA4C749-1F41-4BAC-B17C-75778C013B84Q36277215-87E96FCF-696E-4A59-89BF-07EDD2C1A64AQ36337223-6CDC5561-9E6C-4DF3-980D-34563FD5CEB8Q36345356-AC079DFC-DC03-49F8-B161-ED5913D5DF25Q36426847-1B62301B-F2B3-4599-B897-0613BFC23EBBQ36448703-7685CECE-D16D-455F-BC3C-0A72934DC31EQ36573847-771F09A1-6714-4946-9F9C-ACAE02E3273CQ36971711-13CEFC55-A6FC-41F5-8E3D-1373322825A0Q37011086-1E7DED1A-68DD-4162-936E-D01D26947457Q37085729-D30913CE-FD12-4FF4-977F-B8C156B43E40Q37129057-101AF9B2-2CC4-4F8E-8AA2-ED8A954AA0E0Q37229787-750F2858-3C9F-493B-823E-D8053122C4E2Q37237613-A4A4E618-C17C-4F6F-97DD-A7515AC2886EQ37258214-6383EDA3-267A-40E9-A3FA-EADFD7554DC0Q37316731-6B2B7C46-4528-4080-AE2D-99F803A6D1DFQ37465205-C0451673-4F71-49CA-A39D-ACC118DC3655Q37614753-28147C1B-7EB8-4988-A241-CEFF1628D313Q37768682-AEA7D1CE-D666-4F8A-8AF6-278493778A1CQ37801348-65D0AEA8-28DD-4349-837B-D69A2438FA3EQ37850452-DD4D4DDB-48F4-4E5F-AC09-61272695ADBEQ37944803-B529F74E-3521-4484-9F5B-E8BC9D610AD5Q38034434-0A42F79F-A37F-4826-9132-96331F04D43FQ38661189-C08B915D-5B60-4382-A59C-86B2EBBECC36Q39030384-8C7CF0C0-3515-479B-8A3E-A7BD7DAEF7EBQ41863034-77CFA4F1-3F6F-4602-B9DB-9D0C3DA43AE1Q46320895-CDF054BD-10A3-4B60-88FB-F08177D3314C
P2860
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 September 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The value of PET, CT and in-li ...... atment with imatinib mesylate.
@en
The value of PET, CT and in-li ...... atment with imatinib mesylate.
@nl
type
label
The value of PET, CT and in-li ...... atment with imatinib mesylate.
@en
The value of PET, CT and in-li ...... atment with imatinib mesylate.
@nl
prefLabel
The value of PET, CT and in-li ...... atment with imatinib mesylate.
@en
The value of PET, CT and in-li ...... atment with imatinib mesylate.
@nl
P2093
P2860
P1476
The value of PET, CT and in-li ...... atment with imatinib mesylate.
@en
P2093
Barghouth G
Dizendorf E
Goerres GW
Pestalozzi B
Schnyder P
von Schulthess GK
P2860
P2888
P304
P356
10.1007/S00259-004-1633-7
P577
2004-09-04T00:00:00Z